ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 2,936,875

ZyVersa Therapeutics, Inc. Shares (Diluted, Weighted) is 2,936,875 for the Trailing 12 Months (TTM) ending September 30, 2024, a 6,032.70% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

ZyVersa Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 47,888, a 13.81% change year over year.
ZyVersa Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 42,077.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years